Data Foundry

Medical device recalls 2014

ABX PENTRA Magnesium RTU Reagent — Class II medical device recall Z-2692-2014

Terminated recall by Horiba Instruments, Inc dba Horiba Medical, reported 2014-10-01, distributed nationwide. Horiba Medical is recalling the ABX PENTRA Magnesium RTU Reagent because the on-board stability claims has bee

Recall numberZ-2692-2014
Product typeMedical device
ClassificationClass II
StatusTerminated
Voluntary or mandatedVoluntary
Recalling firmHoriba Instruments, Inc dba Horiba Medical, Irvine, CA, United States
Recall initiated2014-08-11
Classified2014-09-23
Reported by FDA2014-10-01
Terminated2014-11-25
DistributedNationwide (US)
Quantity359 units
Reason classesspecification failure
Model numbersA11A01646

Product

ABX PENTRA Magnesium RTU Reagent, Part No. A11A01646 Product Usage: ABX PENTRA Magnesium RTU reagent with associated calibrators and controls are for quantitative in vitro diagnostic determination of magnesium in human serum and plasma based on a photometric test using xylidyl blue. Magnesium measurements are used in the diagnosis and treatment of hypomagnesemnia (abnormally low plasma levels of magnesium) and hypermagnesemnia (abnormally high plasma levels of magnesium).

Reason for recall

Horiba Medical is recalling the ABX PENTRA Magnesium RTU Reagent because the on-board stability claims has been updated. Horiba has updated the ABX PENTRA Magnesium RTU package inserts by removing the 7-day on-board stability claim and replacing it with a 1-day on-board stability claim.

Machine access

This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/Z-2692-2014. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.

Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.